Previous 10 | Next 10 |
The following slide deck was published by Strongbridge Biopharma plc in conjunction with their 2020 Q1 earnings Read more ...
Strongbridge Biopharma (NASDAQ: SBBP ): Q1 Non-GAAP EPS of -$0.19 beats by $0.04 ; GAAP EPS of -$0.24 beats by $0.05 . More news on: Strongbridge Biopharma plc, Earnings news and commentary, Healthcare stocks news, , Read more ...
~ Phase 3 LOGICS Study of RECORLEV ® (levoketoconazole) Reaches 41 of 42 Targeted Study Participants Completing the Randomized Withdrawal Phase; One Additional Patient Currently in the Randomized Withdrawal Phase and One Other Patient Scheduled to be Randomized Imminently ~ ~ LO...
DUBLIN, Ireland and TREVOSE, Pa., April 20, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced ...
DUBLIN, Ireland and TREVOSE, Pa., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced th...
Strongbridge Biopharma plc (SBBP) Q4 2019 Earnings Conference Call February 25, 2020, 08:30 AM ET Company Participants Lindsay Rocco - Elixir Health Public Relations John Johnson - Executive Chairman Fred Cohen - Chief Medical Officer Scott Wilhoit - Chief Commercial Officer ...
The following slide deck was published by Strongbridge Biopharma plc in conjunction with their 2019 Q4 earnings Read more ...
Strongbridge Biopharma (NASDAQ: SBBP ): Q4 Non-GAAP EPS of -$0.25 beats by $0.02 ; GAAP EPS of -$0.17 beats by $0.23 . More news on: Strongbridge Biopharma plc, Earnings news and commentary, Healthcare stocks news, , Read more ...
~ KEVEYIS ® (dichlorphenamide) Full-Year 2019 Revenue of $21.7 Million, a 29 Percent Increase over 2018 Revenue of $16.8 Million ~ ~ Full-Year 2020 KEVEYIS ® (dichlorphenamide) Revenue Guidance of Approximately $26 to $27 Million; Company Anticipates Continued Pos...
DUBLIN, Ireland and TREVOSE, Pa., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced t...
News, Short Squeeze, Breakout and More Instantly...
Strongbridge Biopharma plc Company Name:
SBBP Stock Symbol:
NASDAQ Market:
Strongbridge Biopharma plc Website:
DUBLIN, Ireland and TREVOSE, Pa., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “Company” or “Strongbridge”) today announced that the High Court of Ireland (the "Court") has approved the previously announced proposed a...
DUBLIN, Ireland and TREVOSE, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “ Company ” or “ Strongbridge ”) today announced that the High Court of Ireland (the “ Court ”) has set the dat...
DUBLIN, Ireland and TREVOSE, Pa., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “ Company ” or “ Strongbridge ”) today announced that its shareholders have voted to approve the previously announced proposed ac...